WallStreetZenWallStreetZen

NASDAQ: AUTL
Autolus Therapeutics PLC Stock

$3.50+0.13 (+3.86%)
Updated Nov 1, 2024
AUTL Price
$3.50
Fair Value Price
$0.92
Market Cap
$931.33M
52 Week Low
$3.06
52 Week High
$7.45
P/E
-2.99x
P/B
1.76x
P/S
88.19x
PEG
N/A
Dividend Yield
N/A
Revenue
$10.50M
Earnings
-$233.98M
Gross Margin
100%
Operating Margin
-1,542.66%
Profit Margin
-2,229%
Debt to Equity
0.62
Operating Cash Flow
-$157M
Beta
1.03
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

AUTL Overview

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AUTL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

AUTL ($3.50) is overvalued by 280.48% relative to our estimate of its Fair Value price of $0.92 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
AUTL ($3.50) is not significantly undervalued (280.48%) relative to our estimate of its Fair Value price of $0.92 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AUTL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AUTL due diligence checks available for Premium users.

Be the first to know about important AUTL news, forecast changes, insider trades & much more!

AUTL News

Valuation

AUTL fair value

Fair Value of AUTL stock based on Discounted Cash Flow (DCF)
Price
$3.50
Fair Value
$0.92
Overvalued by
280.48%
AUTL ($3.50) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AUTL ($3.50) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AUTL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

AUTL price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.99x
Industry
-103.77x
Market
22.23x

AUTL price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.76x
Industry
5.8x
AUTL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

AUTL's financial health

Profit margin

Revenue
$0.0
Net Income
-$58.3M
Profit Margin
0%
AUTL's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
AUTL's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$853.6M
Liabilities
$325.8M
Debt to equity
0.62
AUTL's short-term assets ($758.60M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AUTL's short-term assets ($758.60M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AUTL's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
AUTL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$51.1M
Investing
-$841.0k
Financing
-$2.1M
AUTL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

AUTL vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
AUTL$931.33M+3.86%-2.99x1.76x
CRGX$935.08M+4.46%0.63x2.14x
CGEM$914.87M+1.48%-5.16x1.39x
ZYME$914.69M-3.07%-8.91x2.49x
IMTX$961.98M+2.53%-10.47x2.28x

Autolus Therapeutics Stock FAQ

What is Autolus Therapeutics's quote symbol?

(NASDAQ: AUTL) Autolus Therapeutics trades on the NASDAQ under the ticker symbol AUTL. Autolus Therapeutics stock quotes can also be displayed as NASDAQ: AUTL.

If you're new to stock investing, here's how to buy Autolus Therapeutics stock.

What is the 52 week high and low for Autolus Therapeutics (NASDAQ: AUTL)?

(NASDAQ: AUTL) Autolus Therapeutics's 52-week high was $7.45, and its 52-week low was $3.06. It is currently -53.02% from its 52-week high and 14.38% from its 52-week low.

How much is Autolus Therapeutics stock worth today?

(NASDAQ: AUTL) Autolus Therapeutics currently has 266,094,457 outstanding shares. With Autolus Therapeutics stock trading at $3.50 per share, the total value of Autolus Therapeutics stock (market capitalization) is $931.33M.

Autolus Therapeutics stock was originally listed at a price of $25.00 in Jun 22, 2018. If you had invested in Autolus Therapeutics stock at $25.00, your return over the last 6 years would have been -86%, for an annualized return of -27.94% (not including any dividends or dividend reinvestments).

How much is Autolus Therapeutics's stock price per share?

(NASDAQ: AUTL) Autolus Therapeutics stock price per share is $3.50 today (as of Nov 1, 2024).

What is Autolus Therapeutics's Market Cap?

(NASDAQ: AUTL) Autolus Therapeutics's market cap is $931.33M, as of Nov 4, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Autolus Therapeutics's market cap is calculated by multiplying AUTL's current stock price of $3.50 by AUTL's total outstanding shares of 266,094,457.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.